Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Moderna Files Updated Spikevax for JN.1 Strain in Japan
June 11, 2024
- Rohto Bags Majority Stake in Austria Pharma to Boost European Biz
June 10, 2024
- Towa Files NDA for Rivastigmine Twice Weekly Transdermal Patch in Japan
June 10, 2024
- Novavax COVID Vaccine to Be Adapted to JN.1 Strain: Takeda
June 10, 2024
- Shionogi Gets Option Rights to Cilcare’s Hearing Loss Assets
June 10, 2024
- Maruho Licenses Amenalief Rights in 10 ASEAN States to Singapore Firm
June 7, 2024
- Overseas Sales Ratio of 25 Japan Drug Makers Reaches 67% in FY2023: Tally
June 6, 2024
- TAK-861 Hits Main Goal in PIIb Trial, PIII Set to Begin in 1H FY2024: Takeda
June 6, 2024
- Shionogi to Open Antimicrobial R&D Center in San Diego
June 6, 2024
- Enhertu Scores in Earlier Line for HER2-Low Breast Cancer, Shows Promise in Ultralow Cases
June 6, 2024
- PeptiDream Doses 1st Patient with CA9-Targeted Radiopeptide
June 6, 2024
- Japan Vaccine Market Projected to Top 280 Billion Yen in FY2024: Fuji Keizai
June 6, 2024
- PharmaEssentia’s Besremi Gets Health Coverage for Self-Injection
June 5, 2024
- China Outpaces US in Oncology Trials, Japan’s Share Sags: IQVIA
June 5, 2024
- Twymeeg Tops April GP Rep Promotion Rankings: Intage
June 5, 2024
- Lilly’s Ulcerative Colitis Therapy Omvoh Now Available for Self-Injection
June 4, 2024
- Regeneron Takes Over Japan Marketing Authorization for Libtayo from Sanofi
June 4, 2024
- Organon Launches Fertility Med Follistim after Re-Submission
June 4, 2024
- EU Panel OKs Adzynma for cTTP under Exceptional Circumstances
June 4, 2024
- Janssen Files Amivantamab for Post-Tagrisso NSCLC Setting in Japan
June 3, 2024
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…